Skip to main content

Table 1 Characteristics of the selected systematic reviews

From: Applicability and generalisability of the results of systematic reviews to public health practice and policy: a systematic review

  All reviews N = 98 Cochrane reviews N = 57 Non-Cochrane reviews N = 41 Tobacco use N = 49 HIV infection N = 49
Type of treatment, N (%)      
   Pharmacological treatment 33 (34) 23 (40) 10 (24) 17 (35) 16 (33)
   Nonpharmacological treatment 59 (60) 28 (49) 31 (76) 28 (57) 31 (63)
   Both treatments 6 (6) 6 (10) 0 4 (8) 2 (4)
Therapist-dependent intervention, N (%) 45 (46) 25 (44) 20 (49) 23 (47) 22 (45)
Method of the review, N (%)      
   Quantitative analysis 79 (81) 44 (77) 35 (85) 40 (82) 39 (79.6)
Number of studies included, median (Q1-Q3) 14 (7-25) 9 (5-21) 18 (12-27) 14 (7-26) 14 (7-20)
Trial design, N (%)      
   Randomised controlled trials (RCTs) only 68 (69) 46 (81) 22 (54) 42 (86) 26 (53)
   RCTs + nonrandomized trials 24 (24) 8 (14) 16 (39) 5 (10) 19 (39)
   Nonrandomized trials only 6 (6) 3 (5) 3 (7) 2 (4) 4 (8)
Reporting of key data to describe included studies in a table or figure, N (%) 87 (88) 53 (93) 33 (88) 40 (82) 46 (94)
Internal validity assessment, N (%) 71 (72) 53 (91) 18 (44) 35 (86) 36 (73)
   Quality score 11 (11) 1 (2) 10 (24) 10 (20) 1 (2)
   Allocation sequence generation 44 (52) 37 (65) 7 (17) 30 (61) 14 (29)
   Allocation concealment 59 (58) 51 (89) 8 (19) 31 (63) 28 (57)
   Blinding of participants 21 (21) 17 (30) 4 (10) 6 (12) 15 (31)
   Blinding of care providers 22 (22) 18 (32) 4 (10) 5 (10) 17 (35)
   Blinding of outcome assessors 10 (10) 6 (10) 4 (15) 4 (12) 6 (12)
   Intent-to-treat analysis 13 (13) 8 (14) 5 (12) 5 (10) 8 (16)
Method to account for internal validity, N (%)      
   Sensitivity analysis 8 (8) 3 (5) 5 (12) 4 (8) 4 (8)
   Weighting factor 0 0 0 0 0
   Meta regression 0 0 0 0 0
   Narrative discussion of internal validity 52 (52) 48 (84) 4 (10) 23 (47) 26 (53)
  1. Q1-Q3 = interquartile range 1 to 3